Texas Tech University Health Sciences Center-Amarillo

Summary

Texas Tech University Health Sciences Center-Amarillo is a medical facility located in Amarillo, Texas. This center is recognized for care of Acute Lymphoblastic Leukemia, Leukemia, Soft Tissue Sarcoma, Central Nervous System Tumor, Brain Tumor and other specialties. Texas Tech University Health Sciences Center-Amarillo is involved with conducting 124 clinical trials across 236 conditions. There are 4 research doctors associated with this hospital, such as Samer Zaid Kaylani, Smita Bhaskaran, Alison Lunsford, MD, and Skyler McLaurin-Jiang, MD.

Top PIs

Clinical Trials running at Texas Tech University Health Sciences Center-Amarillo

Wilms Tumor

Testicular cancer

Ovarian Carcinoma

Ovarian Tumors

Testicular Carcinoma

Ovarian Choriocarcinoma

Cancer

Testicular Choriocarcinoma

Kidney Wilms Tumor

Osteosarcoma

Various Treatments

for Wilms Tumor

This phase III trial studies using risk factors in determining treatment for children with favorable tissue (histology) Wilms tumors (FHWT). Wilms Tumor is the most common type of kidney cancer in children, and FHWT is the most common subtype. Previous large clinical trials have established treatment plans that are likely to cure most children with FHWT, however some children still have their cancer come back (called relapse) and not all survive. Previous research has identified features of FHWT that are associated with higher or lower risks of relapse. The term "risk" refers to the chance of the cancer coming back after treatment. Using results of tumor histology tests, biology tests, and response to therapy may be able to improve treatment for children with FHWT.

Recruiting

2 awards

Phase 3

4 criteria

Chemotherapy

for Wilms Tumor

This phase II trial studies how well combination chemotherapy works in treating patients with newly diagnosed stage II-IV diffuse anaplastic Wilms tumors (DAWT) or favorable histology Wilms tumors (FHWT) that have come back (relapsed). Drugs used in chemotherapy regimens such as UH-3 (vincristine, doxorubicin, cyclophosphamide, carboplatin, etoposide, and irinotecan) and ICE/Cyclo/Topo (ifosfamide, carboplatin, etoposide, cyclophosphamide, and topotecan) work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial may help doctors find out what effects, good and/or bad, regimen UH-3 has on patients with newly diagnosed DAWT and standard risk relapsed FHWT (those treated with only 2 drugs for the initial WT) and regimen ICE/Cyclo/Topo has on patients with high and very high risk relapsed FHWT (those treated with 3 or more drugs for the initial WT).

Recruiting

1 award

Phase 2

12 criteria